Bacopa Monnieri

Last reviewed October 2026 · Based on 7 studies

Bottom line

Bacopa is one of the most studied natural nootropics. A 2026 network meta-analysis of 29 trials found high-dose extracts improved working memory in healthy adults, but a 2025 randomised trial found no cognitive benefit at a standard 300 mg dose, so the evidence is mixed. Trials suggest it is generally well tolerated, with digestive complaints the most common side effect.

What it helps with

Improves memory — Mixed results, evidence grade C (Limited). Network meta-analysis of 29 small trials found large effects on working memory, but a 2025 randomised trial found none; downgraded for inconsistent results and high risk of bias.
Speeds up attention and reaction time — Mixed results, evidence grade C (Limited). One meta-analysis found small speed gains, but the newest review found no differences on attention measures and a 2025 trial found no attention benefit; mixed results from small trials.
Reduces stress and fatigue — Benefit, evidence grade C (Limited). Single 12-week randomised trial; stress and fatigue were secondary outcomes, so the finding is preliminary.

What it is

Bacopa monnieri is a plant used in Ayurvedic medicine, where it is called Brahmi, for memory and blood sugar control; its extracts are sold as supplements [1]. Its active compounds include saponins, alkaloids and cucurbitacins [1].

How it might work

Animal studies show promising effects in reducing symptoms and protecting against neurodegeneration, but the mechanisms in humans are not established [1].

What the research says

A 2026 network meta-analysis pooled 29 randomised trials (2,107 healthy adults) comparing Bacopa with Ginkgo biloba. High-dose bacopa (600 mg a day or more) improved working memory versus placebo (standardised mean difference 2.03, 95% CI 1.28-2.78) and versus both ginkgo doses, and improved short-term memory; the lower dose (300 to under 600 mg a day) was best for delayed memory [2]. The authors cautioned that no trial compared the two herbs head to head, making the comparison indirect [2]. An earlier meta-analysis of nine trials (518 people, mostly 12 weeks at 300 mg a day) found only small gains in attention speed — choice reaction time about 10.6 milliseconds faster and a trail-making test about 17.9 milliseconds faster [3]. A 2025 randomised trial in 101 adults with self-reported memory and attention problems found no improvement in verbal learning, attention or working memory after 12 weeks of 300 mg a day, though self-reported stress and task-related fatigue fell [4].

Doses used in studies

Older trials typically used 300 mg a day of standardised extract for at least 12 weeks [3]; the 2026 review's working-memory benefit was seen at 600 mg a day or more [2]. The 2025 trial used 300 mg a day for 12 weeks and found no cognitive effect [4].

Safety and interactions

Common side effects: in a 2025 trial, people taking bacopa reported more side effects than the placebo group, mainly digestive complaints and headaches [4]; a 2025 review describes bacopa as generally non-toxic with no serious side effects reported [1], and older-adult trials reported digestive upset and one withdrawal due to a rash [5].
Upper limits: no established upper intake limit; the 2026 review's trials used 600 mg a day or more [2].
Interactions: a 2025 review notes bacopa can interact with certain medications and should be used cautiously in people with hyperthyroidism [1].
Pregnancy and breastfeeding: safety has not been established, and the review says more research is needed for these groups [1].
Conditions: people with thyroid disease or taking regular medication should check with a doctor first [1].

Caveats and open questions

The evidence is inconsistent: the 2026 review found unusually large memory effects [2], the older meta-analysis found only speed-of-attention gains [3], and the largest recent randomised trial found no cognitive benefit [4]. Most trials in this area are small and at high risk of bias — in one review of 21 herbal cognition trials, 14 were rated high risk [5].